JLL Partners Completes Acquisition of PharmaNet

Tuesday, March 31, 2009 09:36 AM

Contract research organization (CRO) PharmaNet is officially a private company after private equity firm JLL Partners completed its acquisition of the CRO yesterday.

The merger followed the successful completion of JLL’s tender offer to purchase all outstanding PharmaNet shares at a price of $5 per share in cash. The transaction valued the company’s stock at approximately $100 million.

JLL financed the deal with a $250-million equity commitment, including funds to retire the $144 million principal amount of PharmaNet’s outstanding convertible notes. The common stock of PharmaNet ceased trading on the NASDAQ Global Select Market prior to the opening of the market today.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs